CardioVascular BioTherapeutics to Present at 2006 Money Show; Co-Founder to Discuss Treatment Options for Different Types of Cardiovascular Disease.

LAS VEGAS -- CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) announced that Daniel C. Montano, president and CEO, is presenting the progress of the company's drug candidates to treat cardiovascular disease at the 2006 Washington D.C. Money Show. The conference will be held from July 20 to 22, 2006 at the Wardman Park Marriott Hotel in Washington D.C. Mr. Montano is scheduled to speak on July 21 at 10:35 a.m.

"Our primary objective is to revolutionize the medical treatment of cardiovascular disease--the number one cause of death in the U.S.--and help patients experience a better quality of life," said Mr. Montano. "More than $400 billion in costs related to cardiovascular disease are incurred each year in the U.S., and while surgery and medicines are the standard of care to treat cardiovascular disease today, better, safer and lower cost treatment options are needed. We are currently working to evaluate the medical benefits of our protein drug candidates containing Cardio Vascu-Grow(TM), through human clinical trials authorized by the FDA."

CVBT's Cardio Vascu-Grow, a protein member of the fibroblast growth factor family, stimulates the growth of blood vessels in a process called angiogenesis. Once blood perfusion is established in the affected areas, patients with cardiovascular diseases may experience a better quality of life.

The Money Show is one of the largest annual gatherings of investors in the world. This year's event, which focuses on the best new investment strategies for income and growth, provides a unique opportunity for attendees to become informed about trading and investment through interactive panels and discussions.

About CardioVascular BioTherapeutics, Inc.

CVBT is a biopharmaceutical company developing drug candidates with Cardio Vascu-Grow(TM) as the active ingredient for a number of diseases characterized by inadequate blood flow to a tissue or organ. Currently, the company is conducting two FDA-authorized clinical trials: one in coronary artery disease in no-option heart patients, and one in impaired wound healing seen in diabetics. Additionally, the company has completed pre-clinical studies in animal models of peripheral artery disease of the legs and stroke recovery. Clinical trials in these two indications are planned to begin later this year in the U.S. A foreign clinical trial relating to chronic back pain believed to be caused by impaired or blocked arteries has also been initiated.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Cardio Vascu-Grow is a trademark of CardioVascular BioTherapeutics, Inc.